Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Sep 30, 2020
Revenue for the three and nine months ended September 30, 2020 was $1.2 million.
As of September 30, 2020, Adaptimmune had cash and cash equivalents of $78.5 million and Total Liquidity of $399.9 million.
For Fiscal Year Ending Dec 31, 2019
For complete information regarding our financials, see our periodic filings